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Sirs,
Sudden cardiac arrest is a leading cause of death in
developed nations and about 40% of victims present with
ventricular ﬁbrillation at the time of ﬁrst heart rhythm
analysis [4]. Acute myocardial ischemia is generally con-
sidered to be the most common factor triggering fatal
arrhythmias [5]. We report a rare case of sudden cardiac
arrest due to ventricular ﬁbrillation in a patient in whom
diagnostic follow-up led to the diagnosis of a primary
cardiac lymphoma (PCL).
Case report
A 56-year-old Caucasian man was resuscitated at home for
25 min for ventricular ﬁbrillation. Following the admission
to our intensive care unit, he was sedated, intubated and
mechanically ventilated. The initial laboratory measure-
ment revealed a slightly diminished potassium (3.0 mmol/
l), a positive troponin T value, but normal values for
sodium, magnesium, renal function and creatinine kinase.
The echocardiogram showed normal left and right ven-
tricular function and no valvular heart disease. However,
an approximately 4 9 3 cm mass was detected in the apex
of the right ventricle which was conﬁrmed by contrast-
enhanced chest tomography (Fig. 1). Owing to slightly
increasing values of cardiac enzymes, hemodynamic
instability and T-wave inversion in the ECG, the patient
was investigated by coronary angiography leading to the
diagnosis of one-vessel coronary artery disease without the
need of intervention. Angiography of the right ventricle
showed an intraventricular ﬁlling defect following the
injection of contrast medium (Fig. 1). Two biopsies were
taken from the RV mass and the ﬁnal diagnosis was diffuse
large B cell lymphoma (DLBCL) with extranodal mani-
festation at the right ventricular apex, stadium I EB,
international prognostic index of 1. The subsequent clinical
course was uncomplicated and the patient was treated with
six cycles of an anti-CD20/anthracycline-based poly-
chemotherapy (rituxan, cyclophosphamide, doxorubicin,
vincristine, and prednisone every 14 days) without radia-
tion. After completing the last course of chemotherapy,
echocardiography and CT could demonstrate a signiﬁcant
tumor size regression (Fig. 1). After 14 months of com-
pleting chemotherapy, a residual structure in the right
ventricle of approximately 9 9 11 mm was found to be
stable by echocardiography and except for chemotherapy-
related low-grade peripheral polyneuropathia, the patient is
otherwise in good clinical shape and free of symptoms.
Discussion
Primary cardiac tumors are extremely rare and only a
quarter of all cardiac tumors are malignant; 95% of these
are sarcomas, 5% are lymphomas [10]. PCLs are deﬁned as
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involving the heart or the pericardium and usually arise in
the right chambers of the heart [3]. The majority of patients
presents with symptoms of right heart failure [6].
Arrhythmias are mostly described as atrial ﬂatter or
ﬁbrillation, but lymphoma inﬁltration can also cause con-
duction disturbances. However, ventricular ﬁbrillation is
rarely described in the literature. Only one case of sudden
death leading to the post mortem diagnosis of PCL and one
case of ventricular tachycardia are documented in a review
Fig. 1 Upper left panel:
transthoracic echocardiogram
shows an echodense structure in
the right ventricle (arrows).
Upper right panel: right
ventricular angiography
demonstrating an
intraventricular ﬁlling defect
after injection of contrast
medium. Middle panel:
contrast-enhanced computed
tomography demonstrating an
intraventricular ﬁlling defect
after the injection of contrast
material at the time of diagnosis
(left) and after completing the
last course of chemotherapy
(right). Lower panel: histologic
examination of the cardiac
tumor biopsy showed sheets of
large lymphoid cell admixed
with small reactive lymphocytes
[hematoxylin and eosin (a) and
Giemsa (b) stains; 9400
magniﬁcation].
Immunohistochemistry
demonstrated CD20 expression
(c) on neoplastic cells. The
proliferation rate was up to 80%
(d 9400 magniﬁcation)
510 Clin Res Cardiol (2009) 98:509–511
123of 35 patients between 1960 and 2000 [2]. In our patient,
the PCL was localized in the right ventricle. Inﬁltration of
the myocardium and/or conduction system most likely
induced ventricular ﬁbrillation. Echocardiography repre-
sents a very sensitive non-invasive technique for the
identiﬁcation of intracardial tumors, in particular as a ﬁrst
diagnostic approach [8, 9]. Up to 60% of PCLs are found
by transthoracic echocardiography and 97–100% by the
transesophageal approach [3]. Most PCLs are of B cell
lineage and about two-third is diagnosed as DLBCLs [2, 6].
A large study-based evaluation for the optimal therapeutic
option is lacking due to the rarity and heterogeneous his-
tology of PCLs. Ceresoli suggested that PCLs should be
treated like bulky aggressive lymphomas arising in other
primary sites [1]. In a review of 40 cases from 1995 to
2002, chemotherapy alone was applied in 57.5% and in
combination with radiation in 12.5% of patients [6].
Antracycline-based chemotherapy resulted in 61% of
complete remission (mean follow-up 17 months), whereas
surgery did not seem to improve survival at all [1]. Despite
the treatment, approximately 60% of patients died within
2–4 months after diagnosis [2, 6]. Of note, to date the
standard treatment of any DLBCL is an anti-CD20/antra-
cycline-based chemotherapy. Generally, survived cardiac
arrest due to ventricular ﬁbrillation is a class I indication
with evidence level A for an implantable cardioverter
deﬁbrillator (ICD) [7]. However, PCLs per se are associ-
ated with a high-mortality rate within the ﬁrst months after
diagnosis. On the other hand, complete remission should
abolish the arrhythmogenic substrate. In case of lymphoma
recurrence, prognosis would be very limited. Therefore, we
decided against the implantation of an ICD, even if another
episode of ventricular ﬁbrillation may occur.
In conclusion, PCL can be the cause of sudden cardiac
arrest due to ventricular ﬁbrillation. In our patient, an anti-
CD20/antracycline-based chemotherapy led to complete
remission (unconﬁrmed, CRu), and no relapse 14 months
after the initial diagnosis. This case supports that PCL
should be treated like bulky aggressive lymphomas arising
in other primary sites.
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